Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Issue 8 (August 2020)

• Record Type: Journal Article
• Authors: Poynard, Thierry; Peta, Valentina; Deckmyn, Olivier; Pais, Raluca; Ngo, Yen; Charlotte, Frederic; Ngo, An; Munteanu, Mona; Imbert-Bismut, Françoise; Monneret, Denis; Housset, Chantal; Thabut, Dominique; Valla, Dominique; Boitard, Christian; Castera, Laurent; Ratziu, Vlad
• Is Part Of: European journal of gastroenterology & hepatology. Volume 32:Issue 8(2020)
• Publication Date: 2020-08
• Subjects: diabetes -- NashTest -- Obuchowski measure -- spectrum effect -- SteatoTest -- FibroTest; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000001606
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Objective: There is a controversy about the performance of blood tests for the diagnostic of metabolic liver disease in patients with type-2-diabetes in comparison with patients without type-2-diabetes. These indirect comparisons assumed that the gold-standard is binary, whereas fibrosis stages, steatosis and nonalcoholic-steato-hepatitis (NASH) grades use an ordinal scale. The primary aim was to compare the diagnostic performances of FibroTest in type-2-diabetes vs. controls matched on gender, age, fibrosis stages and obesity, and taking into account the spectrum effect by Obuchowski measure. Methods: Data were retrospectively compared among patients prospectively included, with simultaneous biopsy and blindly assessed FibroTest, SteatoTest-2 and NashTest-2. The secondary aim was to construct an index (SpectrumF3F4-Index) to predict an adjusted-area under the receiver operating curve (AUROC) for F3F4 diagnosis from the prevalences of fibrosis stages, permitting to reduce the spectrum effect when performances of FibroTest, transient elastography and magnetic resonance elastography are indirectly compared. Results: In 505 patients at risk of NASH, the Obuchowski measures [95% confidence interval (CI)] of FibroTest, SteatoTest-2 and NashTest-2 were all equivalent in 136 type-2-diabetes cases vs. 369 matched controls: 0.871 (0.837–0.905), vs. 0.880 (0.879–0.881), 0.835 (0.797–0.873) vs. 0.806 (0.780–0.832) and 0.829 (0.793–0.865) vs. 0.855 (0.829–0.869), respectively. Standard-AUROCs (95% CI) were 0.932 (0.898–0.965), 0.872 (0.837–0.907) and 0.834 (0.699–0.969) and reduced after adjustment by SpectrumF3F4-Index to 0.794 (0.749–0.838), 0.767 (0.750–0.783) and 0.773 (0.725–0.822) for transient, magnetic resonance elastography and FibroTest, respectively. Conclusions: When compared by Obuchowski measures, the performances of tests were not different in patients with T2-diabetes vs. patients without T2-diabetes. When individual data are not available, adjusted-AUROCs reduced the spectrum effect. Abstract : Supplemental Digital Content is available in the text.